The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Omacetaxine and azacitidine for newly diagnosed patients with MDS and excess blasts
In this video, Daniel Pollyea, University of Colorado School of Medicine, Denver, CO, comments on the potential of combining omacetaxine and azacitidine for newly diagnosed patients with myelodysplastic syndromes (MDS) and excess blasts. Dr Pollyea highlights that the clinical trial aimed to target MDS stem cells through protein synthesis inhibition, and the results show promising response rates. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI generated)
The omacetaxine plus azacitidine clinical trial came out of an effort to identify stem cells in the MDS population that we could potentially target effectively in a clinical trial. And we found that MDS stem cells do in fact exist. And one potential way to target them is through protein synthesis inhibition. Omacetaxine is a commercially approved protein synthesis inhibitor currently being used for CML patients, but we thought to add it to azacitidine in newly diagnosed high-risk MDS patients with the intention of trying to hit that MDS stem cell population...
The omacetaxine plus azacitidine clinical trial came out of an effort to identify stem cells in the MDS population that we could potentially target effectively in a clinical trial. And we found that MDS stem cells do in fact exist. And one potential way to target them is through protein synthesis inhibition. Omacetaxine is a commercially approved protein synthesis inhibitor currently being used for CML patients, but we thought to add it to azacitidine in newly diagnosed high-risk MDS patients with the intention of trying to hit that MDS stem cell population. And so we did accrue this clinical trial and we’re very hopeful about the response rates that we see. They appear to be higher than what we would expect with azacitidine alone, which is sort of the standard of care in this population. The toxicity profile has been well established. And so we’re hopeful that this type of strategy to target MDS stem cells might be a way forward with other therapies as well.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Syros: Honoraria; Syndax: Honoraria; Sanofi: Honoraria; Boehringer Ingelheim: Honoraria; Aptevo: Honoraria; Bristol Myers Squibb: Honoraria, Research Funding; Sumitomo: Honoraria; Novartis: Honoraria; Rigel: Honoraria; Daiichi Sankyo: Honoraria; MEI: Honoraria; Karyopharm: Honoraria, Research Funding; Qihan: Honoraria; Seres: Honoraria; Gilead: Honoraria; LINK: Honoraria; Adicet: Honoraria; Medivir: Honoraria; Hibercell: Honoraria; Oncoverity: Honoraria; Abbvie: Honoraria, Research Funding; Beigene: Honoraria; Ryvu: Honoraria.
